IL31 and prurigo nodularis: Among these pruritogens, particular attention has been paid to interleukin-31 (IL-31), since systemic administration of the anti-IL-31 receptor A (IL-31RA) antibody nemolizumab successfully ameliorates chronic itch in patients with atopic dermatitis and prurigo nodularis [10,11].